STAT
JANUARY 30, 2024
Ultima Genomics, an upstart some observers have called a “ dark horse ” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT. The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year.
PharmaVoice
JANUARY 30, 2024
Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JANUARY 30, 2024
Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are being studied to treat an entirely different growing health problem: mental health illnesses, including depression and bipolar disorder. Early data and anecdotes suggest that this class of GLP-1 drugs could help patients feel less depressed and anxious.
BioPharma Dive
JANUARY 30, 2024
Since a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for lupus, with more set to start. Here’s why their efforts are worth watching.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JANUARY 30, 2024
NEW YORK — The U.S. syphilis epidemic isn’t abating, with the rate of infectious cases rising 9% in 2022, according to a new federal government report on sexually transmitted diseases in adults. But there’s some unexpected good news: The rate of new gonorrhea cases fell for the first time in a decade.
PharmaVoice
JANUARY 30, 2024
Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The Pharmacist
JANUARY 30, 2024
A total of 10,265 community pharmacies in England will begin offering the new Pharmacy First service from today – marking what has been described as a ‘step-change’ for pharmacies, patients and the public. Among leaders welcoming the new service today is Prime Minister Rishi Sunak who said that with the launch of Pharmacy First the […] The post Over 10,000 pharmacies in England offering Pharmacy First from today appeared first on The Pharmacist.
STAT
JANUARY 30, 2024
In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. government on Tuesday announced a long-awaited “access model” designed to blunt the cost that state Medicaid programs would pay for these curative treatments. Two therapies recently approved by health regulators cost $2.2 million and $3.1 million, respectively, and have raised alarms over the ability of financially strapped state Medicaid programs to absorb the expen
BioPharma Dive
JANUARY 30, 2024
The company plans to soon ask the FDA for approval of the drug, which it has pitched as a safer alternative to addictive opioid painkillers.
STAT
JANUARY 30, 2024
Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval. The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmafile
JANUARY 30, 2024
Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, which allows them to initiate a phase 1 trial of GC012F in the US for the early-line treatment of multiple myeloma (ELMM). GC012F is “an autologous CAR T therapeutic candidate dual-targeting B cell maturation antigen […] The post FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment appeared first on Pha
STAT
JANUARY 30, 2024
A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field. In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo,
Drug Patent Watch
JANUARY 30, 2024
The recent paper published in PLOS ONE presents a novel approach for efficiently retrieving a substantial number of patents related to specific technologies. The authors enhance an automated patent landscaping… The post Revolutionizing Patent Landscaping: A Human-Supervised AI Approach to Identify Tech Clusters appeared first on DrugPatentWatch - Make Better Decisions.
STAT
JANUARY 30, 2024
The ubiquity of AI tools like ChatGPT could be a boon to hospitals eager for diagnostic aids or administrative assistants that can flag crucial medical details and ease the burden of repetitive tasks. But security experts say they can just as easily be harnessed by malicious hackers to exploit an industry known for outdated cyber protections. Health leaders tell STAT they’re assessing risks, recruiting cybersecurity teams and updating training materials to warn staff about increasingly so
The Pharmacist
JANUARY 30, 2024
A new feature of the NHS App will allow patients to view their prescription information digitally and collect their medicines from any pharmacy using a barcode from today. The government said the move would help ‘ease pressures’ on pharmacists and GPs. NHS England (NHSE) is carrying out a full rollout of the added prescription functionality […] The post NHS App launches digital prescription feature appeared first on The Pharmacist.
STAT
JANUARY 30, 2024
John Puisis was dubious when he first heard about the autoimmune science being developed by a coalition of scientists from Northwestern University and the University of Sydney. The group was developing a sort of Trojan horse that it hoped could be used to treat autoimmune diseases. They had developed polymer nanoparticles that could mimic dying cells, which the immune system won’t attack, but will naturally pull from the bloodstream and throw into the body’s waste collection and re
pharmaphorum
JANUARY 30, 2024
From today, a new feature added to the NHS App used in the UK will allow millions of people to submit and view prescriptions, in a bid to save time for patients and doctors. The digital prescription function, which does away with the need for paper scrip, was put through its paces in a pilot trial last year involving a million users of the app, now being used by three-quarters of the UK population or around 33.5 million people.
STAT
JANUARY 30, 2024
Top of the morning to you. And a fine one it is. Despite gray skies, the temperature is gradually rising and a large family of deer is parading alongside the Pharmalot campus, which our official mascots find quite provocative. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own busy agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is cinnamon sticky bun — and attack the fast-growing to-do list.
BioPharma Dive
JANUARY 30, 2024
Roche, Pfizer and Bristol Myers Squibb have all invested in the startup, which is using nanoparticle technology to retrain the body’s immune system.
STAT
JANUARY 30, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with some breathlessly anticipated news from Vertex Pharmaceuticals, an exit interview from an FDA lifer, and the debut of the $100 genome.
pharmaphorum
JANUARY 30, 2024
Explore the future of pharmacovigilance as we begin to shift towards AI-driven processes. Learn about the advancements in AI models, the role of GenAI, and how experts are leveraging these technologies to improve drug safety and monitoring.
STAT
JANUARY 30, 2024
Move over, Kendall Square. Folks in the biotech nerve center may shudder at the notion. But the next miracle drug for lung cancer or epilepsy is just as likely to emerge from Arsenal Yards in Watertown or the shadow of Fenway Park. The spread of the biotech sector — to smaller clusters in Boston, Watertown, Waltham, and beyond — picked up speed in recent years as Cambridge became congested and the cost of lab space skyrocketed.
pharmaphorum
JANUARY 30, 2024
Legislation filed in the US is seeking to block Chinese biotech companies from federal contracts on the grounds they are a national security concern
STAT
JANUARY 30, 2024
WASHINGTON (AP) — The company behind a global recall of sleep apnea machines said Monday it will stop selling the devices in the U.S., under a tentative agreement with regulators that could cost the manufacturer nearly $400 million. Device maker Philips has recalled more than 5 million pressurized breathing machines due to risks that their internal foam can break down over time, leading users to inhale tiny particles and fumes while they sleep.
The Pharmacist
JANUARY 30, 2024
A group of pharmacy technicians at a south coast primary care network (PCN) have been building bridges between community pharmacy, general practice and secondary care settings. Weymouth and Portland PCN has a population of around 78,000 people and 17 pharmacies. And it is where ‘a fantastic, hard-working small team of pharmacy technicians’ have improved working […] The post The pharmacy technicians building bridges across sectors appeared first on The Pharmacist.
pharmaphorum
JANUARY 30, 2024
In a new episode of the pharmaphorum podcast, host Nicole Raleigh speaks with Stuart Cooper, CEO of Adelphi Group, about Anthropy – a yearly event that aims to spark innovation and foster fresh thinking among diverse leaders – and about creating healthier societies, about biopharma’s role in that, including implementation of preventative methods in ameliorating global health.
European Pharmaceutical Review
JANUARY 30, 2024
The European Medicine Agency’s human medicines committee (CHMP) recommended marketing authorisations for the regulatory approval of three medicines at its January 2024 meeting last week. The CHMP recommended Exblifep (cefepime/enmetazobactam) as a treatment for complicated urinary tract infections, including pyelonephritis, hospital-acquired pneumonia, including ventilator associated pneumonia, and for treating bacteraemia caused by the aforementioned infections.
EMCrit Project
JANUARY 30, 2024
Polypharmacy is technically defined as taking five or more medications on a daily basis. Polypharmacy is increasingly becoming the norm among adults, due to several factors (an aging population, increasing numbers of medical problems, and increasingly complex regimens available to treat chronic disorders such as heart failure). Indeed, the term “polypharmacy” is arguably antiquated now […] EMCrit Project by Josh Farkas.
Pharma Times
JANUARY 30, 2024
Type 2 diabetes is estimated to affect 462 million people worldwide
pharmaphorum
JANUARY 30, 2024
Elon Musk’s Neuralink company has said it has implanted its wireless brain implant device into a human being for the first time
PioneerRx
JANUARY 30, 2024
There are many ladders to climb in the pharmacy industry. Clerks can become techs, techs can be lead techs, and lead techs can be pharmacists.
European Pharmaceutical Review
JANUARY 30, 2024
Results from a Phase III, randomised, placebo-controlled clinical trial have for the first time in fifty years, demonstrated an overall survival benefit from an adjuvant therapy in kidney cancer. Pembrolizumab targets a “checkpoint” pathway that is key in enabling cancer cells to avoid being destroyed by the immune system. As a result, the immunotherapy drug supports the immune system’s T cells fight tumours, the researchers highlighted.
The Pharmacist
JANUARY 30, 2024
Nearly 60% of people would be more likely to use the new Pharmacy First service if they better understood how ‘qualified’ teams are to support with minor conditions, research by Superdrug has suggested. The survey, conducted by Superdrug among 937 of its store card members, also found that almost two-thirds (63%) of respondents would use […] The post ‘Clear’ understanding of pharmacists key to Pharmacy First uptake, survey suggests appeared first on The Pharmacist.
Pharmaceutical Technology
JANUARY 30, 2024
The EMA has accepted GSK’s regulatory application seeking expansion of its RSVvaccine, Arexvy, to include adults aged 50 to 59 years.
Express Pharma
JANUARY 30, 2024
The facility will focus on developing next-generation molecules using generative AI platforms, particularly in the ophthalmic, ENT, Paediatrics and skincare segments ENTOD Pharmaceuticals has inaugurated its state-of-the-art Research & Development Centre in Navi Mumbai on Sunday, January 28th. The DSIR approved research laboratory is equipped with the molecular and formulation research tools, microbiology testing facilities, sterile batch production capacity, and high-end quality assurance/q
Expert insights. Personalized for you.
356 
Let's personalize your content